Danazol as First-Line Therapy for Myelodysplastic Syndrome

At present, no standard therapy is available for most patients with myelodysplastic syndrome. In this retrospective study, we analyze data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option because of its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 29, 2017 Category: Hematology Authors: Perla Roc ío Colunga-Pedraza, Julia Esther Colunga-Pedraza, María Alejandra Garza-Ledezma, Jose Carlos Jaime-Pérez, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, Erick Joel Rendón-Ramírez, Yadith Karina López-García, Rosa Elena Tags: Original Study Source Type: research